Reacting to an adverse medical event after it has progressed to causing the patient to seek medical help is the least opportune time to address the underlying disease.

The post From Reactive to Proactive: How Precision Medicine Transforms the Break-and-Fix Healthcare System appeared first on MedCity News.

Now is the time for the entire industry to understand what newborn screening and newborn sequencing programs are, how they benefit the rare disease community, and how to maximize their benefits. 

The post Newborn Screening + Genome Sequencing: The Formula for Faster Rare Disease Diagnosis? appeared first on MedCity News.

Balancing the promise of personalized medicine with proper payment accuracy

The post Navigating the Complexities of Payment for Genetic Testing appeared first on MedCity News.

Labcorp’s $239 million offer was selected as the winning bid for the assets of genetic testing company Invitae, which filed for bankruptcy protection earlier this year. The acquisition deal, Labcorp’s second in the past month, will enable it to expand in oncology and rare diseases.

The post Labcorp Makes Another Acquisition, Plucking Invitae Assets From Bankruptcy Auction appeared first on MedCity News.

Routine NM-MRI for individuals at risk of Parkinson’s could provide a means of identifying the disease before symptoms emerge.

The post Realizing the Promise of Neuromelanin-Sensitive MRI (NM-MRI) appeared first on MedCity News.

Labcorp is buying the clinical diagnostics and reproductive women’s health businesses of BioReference Health, excluding those assets in New York and New Jersey. Labcorp has returned to being fully focused on lab testing after last year’s spinoff of Fortrea, its former clinical trial services business.

The post Labcorp’s $237M Tuck-In Deal Brings Lab Testing Assets From BioReference Health appeared first on MedCity News.

March is Lymphedema Awareness Month, and today there are more options than ever to help prevent this challenging and all too common complication associated with breast cancer treatment.

The post Redefining Survivorship: Proactive Strategies for Preventing Chronic Breast Cancer-Related Lymphedema appeared first on MedCity News.

While the past several decades have seen progress in early detection, recent innovations in metastatic breast cancer—or cancer that has spread to distant parts of the body, including the bone, brain, or lungs—continues to cause excitement.

The post The Future of Innovation Metastatic Breast Cancer: 2024 Outlook appeared first on MedCity News.

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

The post With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge? appeared first on MedCity News.

Private equity is a way to help achieve scale. Groups that use scale to better serve the stakeholders that matter most, including radiologists, hospitals, referring physicians and—most importantly—patients, will be best positioned to not just survive, but thrive.

The post How Access to Capital Benefits Radiology and Radiologists appeared first on MedCity News.

The shift towards digital pathology has marked a significant advancement in breast cancer diagnosis. High-resolution digital imaging of slides provides pathologists with an unprecedentedly clear and expansive view of tissue samples for their analysis.

The post Mitotic Counting Reimagined: When AI Meets the Microscope appeared first on MedCity News.

European Union regulators ordered Illumina to divest Grail. Illumina is appealing antitrust findings in Europe and the U.S., but the DNA sequencing giant revealed that divesting all or part of Grail is an option even if it wins both legal challenges.

The post EU Orders Grail Sale; Illumina Continues Appeals But Plans for Multiple Outcomes appeared first on MedCity News.

Precede Biosciences’ liquid biopsy platform yields insight into the genes and pathways in diseased tissue. Based on Dana-Farber Cancer Institute research, the startup aims to support biopharma drug R&D as it also develops the technology for clinical care applications.

The post Liquid Biopsy Startup Precede Sets Out to Make Precision Medicine More Precise appeared first on MedCity News.

The FDA awarded marketing authorization for a new Invitae test that uses next-generation sequencing to assess multiple genes to identify variants indicating a person’s predisposition for certain cancers. The regulatory action creates a new regulatory classification making Invitae’s test the predicate device for future cancer tests.

The post Invitae’s First of Its Kind Cancer Test Receives FDA Marketing Authorization appeared first on MedCity News.

Standard newborn screening can detect dozens of inherited diseases, but genomics technology enables testing for hundreds of them. A North Carolina program evaluating the feasibility of bringing genomics to newborn screening is expanding with an initial goal of testing 5,000 babies in the next year.

The post How Genome Sequencing Can Broaden the Scope of Newborn Screening appeared first on MedCity News.

Quest Diagnostics is acquiring liquid biopsy company Haystack Oncology. The startup’s technology is used for identifying cancer patients who need adjuvant therapy.

The post Quest Expands in Cancer Testing With $300M Haystack Oncology Acquisition appeared first on MedCity News.

Check out news from BioMEMS Diagnostics, Rx Redefined, Ferrum Health and Avanlee Care.

The post StartUPDATES: New Developments from Healthcare Startups appeared first on MedCity News.

Process improvement and advanced technology can also help relieve the staffing burden that medical laboratories are facing.

The post More Talent and Technology Offer Solutions for Medical Laboratory Staffing Shortages appeared first on MedCity News.

Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.

The post Thermo Fisher bets big on blood cancer, immune diagnostics with $2.6B Binding Site buyout appeared first on MedCity News.

Targeted drugs and immunotherapies are among the advances that contribute to declines in incidence and deaths from non-small cell lung cancer, according to the Annual Report to the Nation on the Status of Cancer. But the trends are on the rise for some other cancers and racial disparities persist, highlighting the need to better understand these differences.

The post Report: Cancer deaths are down but pancreatic cancer is growing, racial disparities persist appeared first on MedCity News.

The breast cancer solution will help determine which patients would benefit from targeted therapies and which patients could avoid chemotherapy. Meanwhile, the colorectal solution will be able to match patients with the most effective treatment sooner.

The post Owkin’s AI solutions for breast and colorectal cancer receive European approval appeared first on MedCity News.

Beyond preparedness policies, we need to think forward to policies that rapidly identify the spread of zoonotic disease to prevent or minimize the impact.

The post A Covid-19 reflection: Incorporating what we’ve learned for improved preparedness appeared first on MedCity News.

Advanced technologies, such as AI-guided robotics and automation, offer a potential solution to the provider shortage by freeing healthcare professionals from repetitive and time-consuming tasks and allow clinicians to focus on tasks that require a specialized touch.

The post Robotics and automation are the future of healthcare appeared first on MedCity News.

Check out new developments from BioMEMS Diagnostics, Neuroflow, Druglike, Health Note, and Rhinostics.

The post StartUPDATES: New developments from healthcare startups appeared first on MedCity News.

Check out news from Equiva, Canvas Medical, Particle Health, Fold Health, and Nucleus Genomics.

The post StartUPDATES: New developments from healthcare startups appeared first on MedCity News.

With the information contained in a simple 30-second voice sample, providers can help patients get ahead of future health issues and prescribe or adjust treatment plans as needed.

The post How vocal biomarkers are becoming a necessary tool for remote patient monitoring appeared first on MedCity News.

MedArrive providers will use Spect’s artificial intelligence-enabled telemedicine platform to screen patients at home for eye diseases such as diabetic retinopathy, glaucoma and age-related macular degeneration.

The post Two firms team up to facilitate at-home screenings to prevent blindness appeared first on MedCity News.

The point of care diagnostics and testing market has climbed dramatically with the rise of the Covid-19 public health crisis. We’re seeking applications for diagnostics startups who would like to take part in INVEST Pitch Perfect Diagnostics 2.0 track at the conference, scheduled to take place March 28-30 in Chicago.

The post Diagnostic startups: Time is running out to apply to INVEST Pitch Perfect appeared first on MedCity News.

It turns out that the laws governing traditional Medicare don’t provide for coverage of self-administered diagnostic tests. Medicare patients are left to seek free tests other ways, including through the administration’s new website, covidtests.gov, and at community centers.

The post Why Medicare does not cover rapid at-home Covid tests appeared first on MedCity News.

The transaction also brought a $200 million investment for Sema4 from life science investors including Pfizer, which can help the combined company’s goal of translating insights from genomics data and analytics into making precision medicine a standard of care.

The post Sema4 secures a deal to acquire GeneDx, capturing $200M in private investment appeared first on MedCity News.